دورية أكاديمية
Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus.
| العنوان: | Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus. |
|---|---|
| المؤلفون: | Chen R; Department of Emergency Medicine, The Sixth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China., Li H; Department of Emergency Medicine, Beijing Luhe Hospital of China Capital Medical University, Beijing, China., Zhu W; Rabies Ward, Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing, China., Cheng H; Department of Emergency Medicine, The Forth Central Hospital of Tianjin, Tianjin, China., Li Y; Institute of Immunization, Beijing Center for Disease Control and Prevention, Beijing, China., Li X; Department of Disease Control, The Fifth Affiliated Hospital of Zhengzhou University, Henan, China., Li F; Vaccine Clinical Research Center of Yunnan Center for Disease Control and Prevention, Yunnan, China., Liu X; Hunan Provincial Center for Disease Control and Prevention, Hunan, China., Hu S; Department of First Aid, The Third Affiliated Hospital of Chongqing Medical University, Sichuan, China., Yan B; Department of Critical Care Medicine, Nanjing Second Hospital, Jangsu, China., Zheng Y; Department of Emergency Surgery, Emergency Physician Branch of Chinese Medical Doctor Association, Beijing Haidian Hospital, Beijing, China., Zuo Y; National Institutes for Food and Drug Control, Beijing, China., Dong G; China Association for Vaccines, Beijing, China., Li X; Division of Infectious Diseases Management, China Center for Disease Control and Prevention, Beijing, China. |
| المصدر: | Expert opinion on drug safety [Expert Opin Drug Saf] 2024 Jun; Vol. 23 (6), pp. 755-762. Date of Electronic Publication: 2023 Jul 12. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London : Ashley Publications, c2002- |
| مواضيع طبية MeSH: | Rabies*/prevention & control , Rabies*/drug therapy , Post-Exposure Prophylaxis*/methods , Rabies virus*/immunology , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects, Humans ; China ; Animals ; Dose-Response Relationship, Drug ; Consensus ; Injections |
| مستخلص: | Background: There are no local or international guidelines or consensus on the use of mAbs against the rabies virus. Research Design and Methods: An expert group in the field of rabies prevention and control formulated the consensus presented in this paper. Results: Class III exposed persons to rabies for the first time; Identify type II exposed persons with immune deficiency; those who are first exposed to Class II and re-exposed to Class III within 7 days. They can use ormutivimab injection after completing the PEP wound treatment. In the case of injection restrictions or a wound that is difficult to detect, it is recommended that the entire Ormutivimab dose be infiltrated close to the wound. For severe multi-wound bites, the recommended dosage of ormutivimab is 20 IU/kg. If the recommended dose cannot meet all of the wound infiltration requirements, appropriate dilution can be conducted at a dilution ratio of 3 ~ 5 times. If the requirements for infiltration cannot be met after dilution, it is recommended that the dosage be increased with caution (maximum dosage, 40 IU/kg). The use of Ormutivimab is safe and effective without any contraindications by all age groups. Conclusions: This consensus standardizes clinical use of Ormutivimab, improves post-exposure prophylaxis of rabies in China, reduces infection rate. |
| فهرسة مساهمة: | Keywords: Anti-rabies monoclonal antibody; clinical application; consensus standardizes in China; ormutivimab; post-exposure prophylaxis; rabies |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) |
| تواريخ الأحداث: | Date Created: 20230710 Date Completed: 20240527 Latest Revision: 20240527 |
| رمز التحديث: | 20240527 |
| DOI: | 10.1080/14740338.2023.2233411 |
| PMID: | 37427985 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-764X |
|---|---|
| DOI: | 10.1080/14740338.2023.2233411 |